监测与积极治疗之间近最优选择的试验规模：重新审视MSLT-II
重新分析MSLT-II试验样本规模，比较淋巴结观察与清扫治疗皮肤黑色素瘤，提出更小的最优样本量。
基本信息
资源简介
监测与积极治疗之间近最优选择的试验规模：重新审视MSLT-II
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 1 个文件、合计 13.71 KB，主题涵盖 Analysis of treatment response、Clinical trials、Medical decisions、Minimax regret、Sample size，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Trial Size for Near-Optimal Choice Between Surveillance and Aggressive Treatment: Reconsidering MSLT-II》。配套论文《Trial Size for Near-Optimal Choice Between Surveillance and Aggressive Treatment: Reconsidering MSLT-II》发表于 The American Statistician（2019），DOI：10.1080/00031305.2018.1543617。源站首次发布：2019-03-21。
【数据内容】
源站原始描述：A convention in designing randomized clinical trials has been to choose sample sizes that yield specified statistical power when testing hypotheses about treatment response. Manski and Tetenov recently critiqued this convention and proposed enrollment of sufficiently many subjects to enable near-optimal treatment choices. This article develops a refined version of that analysis applicable to trials comparing aggressive treatment of patients with surveillance. The need for a refined analysis aris…
【数据结构与技术规格】
文件数 1 个，合计 13.71 KB。TAS-18-286-code.zip：application/zip，13.71 KB。数据集 DOI：10.6084/m9.figshare.7871957.v1。
【主题与分类】
源站学科分类：Medicine、Neuroscience、Pharmacology、Biotechnology、Cancer、Science Policy。主题标签：Analysis of treatment response、Clinical trials、Medical decisions、Minimax regret、Sample size。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://tandf.figshare.com/articles/dataset/Trial_Size_for_Near-Optimal_Choice_Between_Surveillance_and_Aggressive_Treatment_Reconsidering_MSLT-II/7871957
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Trial Size for Near-Optimal Choice Between Surveillance and Aggressive Treatment: Reconsidering MSLT-II. Taylor & Francis. Manski, Charles F.; Tetenov, Aleksey
【使用注意】
· 源站最后修改于 2026-07-08，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Trial Size for Near-Optimal Choice Between Surveillance and Aggressive Treatment: Reconsidering MSLT-II
- DOI：10.6084/m9.figshare.7871957.v1
- 发布日期：2019-03-21
- 文件数：1 个
- 文件总体积：13.71 KB
- 源站页面：https://tandf.figshare.com/articles/dataset/Trial_Size_for_Near-Optimal_Choice_Between_Surveillance_and_Aggressive_Treatment_Reconsidering_MSLT-II/7871957
命令行下载
curl -L -o "TAS-18-286-code.zip" "https://ndownloader.figshare.com/files/14657573"
文件清单
TAS-18-286-code.zip（13.71 KB）
文件总体积 13.71 KB（源站 API 实测）。
数据说明
A convention in designing randomized clinical trials has been to choose sample sizes that yield specified statistical power when testing hypotheses about treatment response. Manski and Tetenov recently critiqued this convention and proposed enrollment of sufficiently many subjects to enable near-optimal treatment choices. This article develops a refined version of that analysis applicable to trials comparing aggressive treatment of patients with surveillance. The need for a refined analysis arises because the earlier work assumed that there is only a primary health outcome of interest, without secondary outcomes. An important aspect of choice between surveillance and aggressive treatment is that the latter may have side effects. One should then consider how the primary outcome and side effects jointly determine patient welfare. This requires new analysis of sample design. As a case study, we reconsider a trial comparing nodal observation and lymph node dissection when treating patients with cutaneous melanoma. Using a statistical power calculation, the investigators assigned 971 patients to dissection and 968 to observation. We conclude that assigning 244 patients to each option would yield findings that enable suitably near-optimal treatment choice. Thus, a much smaller sample size would have sufficed to inform clinical practice.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.7871957.v1（source: https://tandf.figshare.com/articles/dataset/Trial_Size_for_Near-Optimal_Choice_Between_Surveillance_and_Aggressive_Treatment_Reconsidering_MSLT-II/7871957）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
